Press release
Progressive Fibrosing Interstitial Lung Disease Market Size was USD 4,205 Million in 2021
The Progressive Fibrosing Interstitial Lung Disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Progressive Fibrosing Interstitial Lung Disease market size from 2019 to 2032. The Report also covers current Progressive Fibrosing Interstitial Lung Disease treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Key takeaways from the Progressive Fibrosing Interstitial Lung Disease Market
• As per DelveInsight analysis, the progressive fibrosing interstitial lung disease market size in the 7MM was approximately USD 4,205 million in 2021.
• As per the estimates, the total progressive fibrosing interstitial lung disease diagnosed prevalent cases in the 7MM were approximately 322K in 2021.
• Leading progressive fibrosing interstitial lung disease companies include Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb along with IPF-specific PF-ILD like Hoffmann-La Roche Ltd, FibroGen, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, and others
• The progressive fibrosing interstitial lung disease therapies in the pipeline include BI 1015550, BMS-986278 along with IPF-specific PF-ILD drugs like Pamrevlumab, PRM-151 (RG6354), PLN-74809, Tyvaso (inhaled treprostinil), C21 (VP01), and others.
For more insights into the Progressive Fibrosing Interstitial Lung Disease Market Landscape, visit Progressive Fibrosing Interstitial Lung Disease Market Therapeutics Landscape @ https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Progressive Fibrosing Interstitial Lung Disease Overview
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consist of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality. Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible.
Progressive Fibrosing Interstitial Lung Disease Epidemiology Segmentation in the 7MM
• Total Progressive Fibrosing Interstitial Lung Disease Prevalent Cases
• Total Progressive Fibrosing Interstitial Lung Disease Diagnosed Prevalent Cases
• Progressive Fibrosing Interstitial Lung Disease Type-specific Diagnosed Prevalent Cases
• Total Progressive Fibrosing Interstitial Lung Disease Diagnosed Prevalent Cases
To know more information of the Progressive Fibrosing Interstitial Lung Disease Epidemiology Segmentation of the report, click here for Progressive Fibrosing Interstitial Lung Disease Epidemiology Insights @ https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Progressive Fibrosing Interstitial Lung Disease Treatment Market
PF-ILD treatments that act on the fibrotic pathway are required to slow the progression of fibrosis. This justifies further research into pirfenidone and nintedanib, both of which have been shown to slow disease progression in IPF patients. Other than IPF, there are few treatment options for advanced fibrotic ILD. Pirfenidone use in PPF patients is associated with a statistically significant reduction in disease progression and protection of lung function.
Progressive Fibrosing Interstitial Lung Disease Market Dynamics
The growing prevalence of PF-ILD worldwide, due to delayed accurate diagnosis and the lack of curative treatment options for ILDs, is likely to increase the demand for treatment options in the progressive fibrosing interstitial lung disease market. As a result, the revenue-progressive fibrosing interstitial lung diseases market may increase in the coming years.
Browse More Related Reports of the Progressive Fibrosing Interstitial Lung Disease Market Research Reports, click here for Progressive Fibrosing Interstitial Lung Disease Market Forecast @ https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Progressive Fibrosing Interstitial Lung Disease Market Report
• Coverage- 7MM
• Progressive Fibrosing Interstitial Lung Disease Companies- Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb along with IPF-specific PF-ILD like Hoffmann-La Roche Ltd, FibroGen, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, and others
• Progressive Fibrosing Interstitial Lung Disease Pipeline Therapies- BI 1015550, BMS-986278 along with IPF-specific PF-ILD drugs like Pamrevlumab, PRM-151 (RG6354), PLN-74809, Tyvaso (inhaled treprostinil), C21 (VP01), and others.
• Progressive Fibrosing Interstitial Lung Disease Market Dynamics: Progressive Fibrosing Interstitial Lung Disease Market Drivers and Barriers
• Progressive Fibrosing Interstitial Lung Disease Market Access and Reimbursement, Unmet Needs
Read the Full Research Report of the Progressive Fibrosing Interstitial Lung Disease Market Forecast Report, click here for Progressive Fibrosing Interstitial Lung Disease Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Report Introduction
3. Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) Market Overview at a Glance
4. Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Market: Future Perspective
5. Executive Summary of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
6. Key Events
7. Disease Background and Overview: Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Drugs
12. Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Seven Major Market Analysis
13. Key Opinion Leaders' Views
14. Market Drivers
15. Market Barriers
16. SWOT Analysis
17. Unmet Needs
18. Reimbursement and Market Access
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Consult with our Business Expert regarding "Progressive Fibrosing Interstitial Lung Disease Market Landscape" @ https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Trending Market Reports in 2023
Healthcare Partner Identification Services @ https://www.delveinsight.com/consulting/partner-identification-services
Medical Marijuana Market @ https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Oncolytic Virus Cancer Therapy Pipeline @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021
Overactive Bladder Syndrome Market @ https://www.delveinsight.com/report-store/overactive-bladder-market
Pediatric Growth Hormone Deficiency PGHD Market @ https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
Percutaneous Arterial Closure Device Market @ https://www.delveinsight.com/report-store/percutaneous-arterial-closure-device-market
Ranibizumab Biosimilars Insight @ https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
Schistosomiasis Market @ https://www.delveinsight.com/report-store/schistosomiasis-market
Stem Cell Market @ https://www.delveinsight.com/report-store/stem-cell-market
Superficial Punctate Keratitis Market @ https://www.delveinsight.com/report-store/superficial-punctate-keratitis-market
Technical Due Diligence @ https://www.delveinsight.com/consulting/due-diligence-services
Transient Ischemic Attack Market @ https://www.delveinsight.com/report-store/transient-ischemic-attack-market
Wilms Tumor Market @ https://www.delveinsight.com/report-store/wilms-tumor-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Progressive Fibrosing Interstitial Lung Disease Market Size was USD 4,205 Million in 2021 here
News-ID: 2984942 • Views: …
More Releases from DelveInsight Business Research
Urticaria Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Ap …
As per DelveInsight's assessment, globally, Urticaria pipeline constitutes 20+ key companies continuously working towards developing 25+ Urticaria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Urticaria Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Urticaria Market.
The Urticaria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from…
Artificial Intelligence (AI) in Remote Patient Monitoring Market is expected to …
DelveInsight's "Artificial Intelligence (AI) in Remote Patient Monitoring Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Remote Patient Monitoring companies actively working in the market.
According to DelveInsight's analysis, The AI in Remote Patient Monitoring market, valued at USD 1,926.51 million in…
Artificial Intelligence (AI) in Precision Medicine Market is expected to reach U …
DelveInsight's "Artificial Intelligence (AI) in Precision Medicine Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Precision Medicine companies actively working in the market.
According to DelveInsight's analysis, The AI in Precision Medicine market, valued at USD 1,036.91 million in 2024, is expected…
AI in Diagnostics market is expected to reach USD 8,081.97 million by 2032 | Del …
DelveInsight's "Artificial Intelligence (AI) in Diagnostics Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Diagnostics companies actively working in the market.
DelveInsight Analysis: The AI in Diagnostics market, valued at USD 1,623.20 million in 2024, is projected to expand at a compound…
More Releases for Progressive
Progressive Insurance Market Is Booming So Rapidly | Major Giants Progressive Co …
HTF MI just released the Global Progressive Insurance Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Key Players in This Report Include:
Progressive Corporation, State Farm, Allstate, GEICO,…
Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2024 - …
"The progressive multifocal leukoencephalopathy treatment market size has grown rapidly in recent years. It will grow from $1.31 billion in 2023 to $1.46 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to prevalence of underlying conditions, rise in immunosuppressed patients, patient advocacy and awareness, rise of hiv/aids epidemic.
The progressive multifocal leukoencephalopathy treatment market size is…
Progressive Multifocal Leukoencephalopathy Treatment Market Size 2034
DelveInsight's 'Progressive Multifocal Leukoencephalopathy Market Insights, Epidemiology, and Market Forecast - 2034' report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Progressive Multifocal Leukoencephalopathy in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Key Takeaways from the Progressive Multifocal Leukoencephalopathy Market Report
• According to DelveInsight's analysis, the incident cases of PML in the 7MM were approximately 4…
Seminar on Progressive Farming
Shri Venkateshwara University/VGI Meerut in collaboration with Bhartiya Kisan Union (Meerut Division) is organizing a 1 day seminar on Progressive farming & farmer the foundation of development on Nov 3rd.In this seminar, the National Organization Minister of All India Farmer's Organization Mr Dinesh Kulkarni, Padamshree Mr Bharat Bhushan Tyagi, & the State Agriculture Minister Mr Baldev Singh Aulakh will take part.Apart from these renowned agriculture scientists, environmentalists, bureaucrats & 400…
Progressive Supranuclear Palsy Headed Toward Cure
Progressive supranuclear palsy (PSP) is a brain disorder which impacts vision, cognition, movement, and speech. This disease results in weakness by affecting certain parts of the brain above the cell clusters, known as nuclei (supranuclear), which are involved in controlling eye movements. It usually manifests in mid-to late adulthood, and the survival rate of people suffering from PSP is five to nine years after the disease first appears. It is…
Progressive Personnel rebrands to Progressive Travel Recruitment
Global travel and hospitality recruitment leader, Progressive Personnel, this month re-emerges as Progressive Travel Recruitment with a fresh new look and a new website under the new URL – www.progressivetravelrecruitment.com – with enhanced job search capability.
Progressive Travel Recruitment’s competitive edge, however, remains – a dedicated team of specialist travel recruiters, who have themselves worked in the industry and understand intimately the needs of travel companies and travel candidates, and…
